KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Current Deferred Revenue (2019 - 2023)

GoodRx Holdings' Current Deferred Revenue history spans 5 years, with the latest figure at $10.8 million for Q1 2023.

  • On a quarterly basis, Current Deferred Revenue rose 4.3% to $10.8 million in Q1 2023 year-over-year; TTM through Mar 2023 was $10.8 million, a 4.3% increase, with the full-year FY2022 number at $7.9 million, up 15.01% from a year prior.
  • Current Deferred Revenue hit $10.8 million in Q1 2023 for GoodRx Holdings, up from $7.9 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for GDRX hit a ceiling of $11.5 million in Q2 2022 and a floor of $3.5 million in Q4 2019.
  • Historically, Current Deferred Revenue has averaged $8.5 million across 5 years, with a median of $8.5 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: soared 98.44% in 2020 and later increased 0.25% in 2021.
  • Tracing GDRX's Current Deferred Revenue over 5 years: stood at $3.5 million in 2019, then soared by 98.44% to $6.9 million in 2020, then increased by 0.25% to $6.9 million in 2021, then increased by 15.01% to $7.9 million in 2022, then soared by 36.24% to $10.8 million in 2023.
  • Business Quant data shows Current Deferred Revenue for GDRX at $10.8 million in Q1 2023, $7.9 million in Q4 2022, and $11.0 million in Q3 2022.